Back to News
Market Impact: 0.12
A*STAR and Mirai Bio to Jointly Advance Research on Nucleic Acid Delivery to the Lung
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Mirai Bio and Singapore's A*STAR IMCB announced a collaboration to advance targeted nucleic-acid delivery technologies for lung epithelial and endothelial cells. The partnership supports preclinical biotech innovation but disclosed no financial terms, clinical data, commercialization timeline, or expected revenue impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Wall Street’s Nasdaq hits all-time high as AI frenzy gathers pace
- Data-Center Bet Makes ESDS One of India’s Best New Listings
- Asia stocks ride tech wave higher, oil stays subdued
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Heidi CEO on AI in Healthcare, $900M valuation